Heron Therapeutics (FRA:AXD2) Other Stockholders Equity: €-0.0 Mil (As of Mar. 2026)


FRA:AXD2 Heron Therapeutics Inc FRA:AXD2
49 GF Score
Price €0.37
GF Value €1.37
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Heron Therapeutics Other Stockholders Equity?

Heron Therapeutics FRA:AXD2 -3.88% 49 Other Stockholders Equity is €-0.0 Mil as of Mar. 2026. GuruFocus rates FRA:AXD2 with a GF Score™ of 49/100 and a GF Value™ of €1.37 (Possible Value Trap). The stock has 4 warning signs investors should review.

Heron Therapeutics's Other Stockholders Equity for the quarter that ended in Mar. 2026 was €-0.0 Mil.

Heron Therapeutics's quarterly Other Stockholders Equity declined from Sep. 2025 (€-0.0 Mil) to Dec. 2025 (€-0.0 Mil) and declined from Dec. 2025 (€-0.0 Mil) to Mar. 2026 (€-0.0 Mil).

Heron Therapeutics's annual Other Stockholders Equity declined from Dec. 2023 (€0.0 Mil) to Dec. 2024 (€-0.0 Mil) but then increased from Dec. 2024 (€-0.0 Mil) to Dec. 2025 (€-0.0 Mil).

Heron Therapeutics Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Heron Therapeutics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Heron Therapeutics Other Stockholders Equity Chart

Heron Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 0.00 0.00 -0.00 -0.00

Heron Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 0.00 -0.00 -0.00 -0.00
FRA:AXD2
49GF Score
Heron Therapeutics Inc FRA:AXD2
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Heron Therapeutics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €-0.0 Mil mean?
Heron Therapeutics (FRA:AXD2) has a Other Stockholders Equity of €-0.0 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Heron Therapeutics and its competitors.
Is Heron Therapeutics' Other Stockholders Equity too high?
Heron Therapeutics' current Other Stockholders Equity is €-0.0 Mil. Overall, Heron Therapeutics has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Heron Therapeutics' Other Stockholders Equity compare to ENTX and OKYO?
Heron Therapeutics' Other Stockholders Equity of €-0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Heron Therapeutics and its competitors. Heron Therapeutics's current Other Stockholders Equity is €-0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Heron Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Heron Therapeutics (FRA:AXD2) is currently considered Possible Value Trap. The stock's GF Value™ is €1.37, compared to a current price of €0.37 — trading 73.3% below its estimated fair value. The current Other Stockholders Equity is €-0.0 Mil. Heron Therapeutics' overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Heron Therapeutics (FRA:AXD2), the current Other Stockholders Equity is €-0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Heron Therapeutics (FRA:AXD2) Overvalued in 2026?

Based on GuruFocus' analysis, Heron Therapeutics stock appears to be undervalued. The current stock price of €0.37 is trading 73.3% below its estimated GF Value™ of €1.37. GuruFocus considers Heron Therapeutics to be Possible Value Trap.

Key valuation signals for FRA:AXD2:

  • Other Stockholders Equity: €-0.0 Mil
  • GF Value™: €1.37 vs. price of €0.37 (73.3% below fair value)
  • GF Score™: 49/100 with 4 warning signs

No single metric tells the full story. See the FRA:AXD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Heron Therapeutics Business Description

Other Exchanges HRTX:USA0J4V:UKAXD2:Germany
Address 100 Regency Forect Drive, Suite 300, Cary, NC, USA, 27518
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
49GF Score

Get the complete analysis for FRA:AXD2

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.37
Price
€1.37
GF Value